ClinicalTrials.gg
RecruitingNCT06772025Updated Oct 27, 2026

A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine

An interventional study of No investigational study intervention in Cardiac Surgery-associated Acute Kidney Injury, sponsored by Bayer. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Bayer · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 27, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 77 studies in Acute Kidney Injury with a site in United Kingdom — 16 open to participants now, 21 under way, none of them phase 3. Acute Kidney Injury · United Kingdom.

Planned enrollment
16th of 31
100 · median 100
Started
2025
with 5 others
No phase
17 of 77
6 open now
Primary completion
2027-01
later than 11 of 20 live
Registered
66th of 77
by date

Among the 77 studies in Acute Kidney Injury with a site in United Kingdom, this one is the 16th largest by planned enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2025, is one of 17 with no phase, reaches primary completion later than 11 of the 20 other live ones, and was the 66th registered.

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

16 of the 77 studies in Acute Kidney Injury with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Acute Kidney Injury with a site in United Kingdom, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat and prevent cardiac surgery-associated acute kidney injury (CSA-AKI) in people who undergo heart surgeries.

CSA-AKI is a common complication in people undergoing heart surgeries, where the kidneys stop working properly. CSA-AKI risk factors include older age and alongside diseases such as kidney disease and diabetes. Longer time with heart-lung machine during heart surgeries also increases the occurrence of CSA-AKI.

In this study, researchers want to better understand how CSA-AKI develops (also known as the mechanisms involved in the development of CSA-AKI) in people under heart surgeries, the presence of certain biomarkers in the body, especially with a focus on the early hours and days after the surgery. (A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.) These biomarkers will be compared in participants who develop CSA-AKI within a week after heart surgery with the participants who do not develop CSA-AKI. The relationship with biomarkers will be determined by examining participants' blood and urine samples before and after surgery.

This may help researchers better understand CSA-AKI, identify potential treatment targets and develop possible treatments to prevent CSA-AKI.

Participants in this study will be people who have heart surgery already scheduled by their own doctors and have a risk of developing CSA-AKI. Participants will not receive any treatment as part of this study. They will undergo the heart surgery and related medical processes as per their normal medical treatment and management.

Each participant will be in the study for up to 2 months. During the study, the doctors and their study team will:

  • collect participants' blood and urine samples before and after surgery
  • assess participants' medical records and test reports during hospitalization
  • monitor overall health of the participants throughout the study
03

Conditions studied

  • Cardiac Surgery-associated Acute Kidney Injury

Browse trials for

Keywords

  • CSA-AKI
  • Cardiac surgery
  • Cardiopulmonary bypass
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 18 years of age at the time of signing the form (ICF).
  • Participants who are scheduled for hospital admission for any of the following cardiovascular surgery interventions, alone or in combination, involving cardiopulmonary bypass (CPB):

    • Aortic, mitral, or tricuspid valve surgery (repair or replacement)
    • Aortic surgery
    • ≥3 coronary artery bypass grafts
  • Participant with: chronic kidney disease (CKD): 30 ≤ estimated (eGFR) \< 90 mL/min/1.73 m\^2

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery situation
  • Anemia - \<10 g/dL
  • Clinical signs of systemic infection or other infection requiring anti-infective treatment (viral, bacterial, fungal, parasitic; single-dose prophylaxis allowed)
  • Systemic or anti-inflammatory treatment including >10 mg prednisolone equivalent/day
  • Any anti-cancer treatment within 3 months (e.g. immunotherapy, chemotherapy, radiotherapy)
  • Major surgery within 2 months
  • AKI within the last month
  • Prior renal transplants or RRT
  • Planned use of contrast media within 5 days prior to surgery or during surgery
  • Patient included in an interventional clinical trial involving a pharmacological intervention
  • Any reason that would make participation unadvisable, at the discretion of the investigator.
  • disorders such as anti-glomerular basement membrane (anti-GBM) diseases, systemic lupus erythematosus, chronic rheumatic heart diseases, acute rheumatic heart pericarditis, endocarditis, myocarditis, rheumatic mitral valve diseases, rheumatic aortic valve diseases
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cardiac surgery

    Patients scheduled for cardiac surgery with cardiopulmonary bypass will be managed according to local standard medical care. Blood and urine will be obtained pre-surgery and post-surgery for analysis.

    Other: No investigational study intervention

Interventions

  • OtherNo investigational study intervention

    No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 200 mL) and urine samples and of available clinical data are the only activities performed in addition.

06

What researchers measure

Primary outcomes

  1. Number of participants with CSA-AKI until Day 3 post-surgery

    CSA-AKI: cardiac surgery-associated acute kidney injury

    Time frame: Up to 3 days post surgery

Secondary outcomes

  1. Observed values of pre-defined biomarkers overall and by CSA-AKI outcome

    Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury

    Time frame: Up to 7 days post surgery

  2. Change from baseline of pre-defined biomarkers overall and by CSA-AKI outcome

    Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury

    Time frame: Up to 7 days post surgery

  3. Ratio to baseline of pre-defined biomarkers overall and by CSA-AKI outcome

    Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury

    Time frame: Up to 7 days post surgery

07

Study locations

4 of 4 sites recruiting
  • Herz- und Diabeteszentrum Nordrhein-Westfalen
    Bad Oeynhausen, North Rhine-Westphalia 32545, Germany
    Recruiting
  • Royal Papworth Hospital | Cardiac Surgery
    Cambridge, Cambridgeshire CB2 0AY, United Kingdom
    Recruiting
  • Harefield Hospital | Cardiology
    Harefield, Greater London UB9 6JH, United Kingdom
    Recruiting
  • St Thomas' Hospital | Critical Care
    London, Greater London SE1 7EH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 268 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 13, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
200→100
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Enrollment 200→100
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06772025
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Feb 3, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion